The Bell Tolls For Fedratinib In A Setback For Sanofi’s Oncology Portfolio

The company has halted clinical trials testing its Phase III JAK2 inhibitor fedratinib after determining that the risks of treatment outweigh the benefit after cases of the neurological condition Wernicke’s encephalopathy emerged in patients.